Renalfarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,807,353 | 1,815,048 | 2,026,719 | 1,947,544 | 1,921,403 | 2,053,315 | 2,010,833 | 2,451,901 |
| Profit before tax | 31,322 | 53,927 | 122,858 | 118,860 | 65,006 | 154,130 | 188,260 | 347,696 |
| Net profit | 25,661 | 46,881 | 108,018 | 102,134 | 56,157 | 131,571 | 161,594 | 292,898 |
| Equity | 126,142 | 137,023 | 231,041 | 245,176 | 266,333 | 356,905 | 398,499 | 441,398 |
| Liabilities | 524,762 | 463,561 | 557,127 | 659,077 | 477,046 | 275,860 | 267,819 | 479,039 |
| Non-current assets | 73,804 | 66,691 | 105,589 | 181,540 | 135,441 | 104,683 | 75,338 | 46,037 |
| Current assets | 575,114 | 532,207 | 680,532 | 719,484 | 604,633 | 525,517 | 588,206 | 872,215 |
| Total assets | 648,918 | 598,898 | 786,121 | 901,024 | 740,074 | 630,200 | 663,544 | 918,252 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 143,487 | 160,754 | 226,911 |
| Social insurance contributions | - | - | - | - | - | 57,341 | 56,937 | 63,922 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +27.7% | +0.4% | +11.7% | -3.9% | -1.3% | +6.9% | -2.1% | +21.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.0% | 7.8% | 13.7% | 11.3% | 7.6% | 20.9% | 24.4% | 31.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 20.3% | 34.2% | 46.8% | 41.7% | 21.1% | 36.9% | 40.6% | 66.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.4% | 2.6% | 5.3% | 5.2% | 2.9% | 6.4% | 8.0% | 11.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.7% | 3.0% | 6.1% | 6.1% | 3.4% | 7.5% | 9.4% | 14.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 4.2 | 3.4 | 2.4 | 2.7 | 1.8 | 0.8 | 0.7 | 1.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 301,226 | 302,508 | 386,042 | 359,544 | 320,234 | 342,219 | 395,576 | 490,380 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Renalfarma - Social security debts
The company had no debts to Sodra
Renalfarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Renalfarma, UAB (code 301485538) is a private limited liability company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €2.45M, up 21.9% year on year and 19.4% over two years. Net profit reached €292.9K, with a profit margin of 11.9%, improving from €161.6K in 2024 and €131.6K in 2023. The three-year trend shows a dip in revenue in 2024 followed by a strong rebound in 2025, while profitability rose steadily each year and margins expanded from 6.4% in 2023 to 8.0% in 2024 and 11.9% in 2025. At the end of 2025, total assets stood at €918.3K, equity at €441.4K, and liabilities at €479.0K. The equity ratio was 48.1% and debt-to-equity 1.09, indicating a balanced capital structure. Asset turnover was 2.67x, ROE 66.4% and ROA 31.9%. Revenue per employee was €490.4K, with profit per employee of €58.6K.